AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29659102
Drug: Antidepressants across
RxNorm normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antidepressants across severity levels for SAD
Trial: 29659102
Drug: Antidepressants across
RxNorm normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antidepressants across severity levels for OCD
Trial: 29659102
Drug: Antidepressants across
RxNorm normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antidepressants across severity levels for PTSD
Trial: 29659330
Drug: DD4A chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DD4A chemotherapy (vincristine/dactinomycin/doxorubicin) without lung radiation therapy for patients with CR.
Trial: 29659330
Drug: DD4A chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DD4A chemotherapy plus lung radiation therapy and four cycles of cyclophosphamide/etoposide for patients with IR.
Trial: 29659330
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment strategy of AREN0533.
Trial: 29659889
Drug: Convalescent plasma
RxNorm normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convalescent plasma (ECP) with higher anti-EBOV antibody levels
Trial: 29659889
Drug: Convalescent plasma
RxNorm normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convalescent plasma (ECP) with lower anti-EBOV antibody levels
Trial: 29659964
Drug: Universal salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Universal salt iodization (USI) with salt iodine concentration at ∼25 mg/kg
Trial: 29660005
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment (Cabozantinib monotherapy)
Trial: 29661508
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment upon disease progression to Gleason 7 (3+4)
Trial: 29661508
Drug: Consensus on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consensus on follow-up protocols and active treatment criteria
Trial: 29661699
Drug: Sacubitril/valsartan (97
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacubitril/valsartan (97 mg/103 mg twice daily)
Trial: 29662875
Drug: Protease inhibitor-based
RxNorm normalized name: Protease inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease inhibitor-based second-line regimen with adherence counseling for 3 months
Trial: 29662960
Drug: Oral hygiene
RxNorm normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hygiene discontinuation for 10 days
Trial: 29664672
Drug: Primary care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary care management of sleep apnea, details on dosage and duration not available
Trial: 29664672
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care for sleep apnea, details on dosage and duration not available
Trial: 29664709
Drug: G1XCGD, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G1XCGD, a lentiviral vector for ex vivo gene therapy
Trial: 29665842
Drug: Sensory re-learning
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sensory re-learning in combination with task-specific training
Trial: 29665840
Drug: Cyclosporine A
RxNorm normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine A pretreatment (2.5 mg/kg) in deceased organ donors
Trial: 29666296
Drug: Rilotumumab (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilotumumab (20 mg/kg) and Bevacizumab (10 mg/kg) every 2 weeks
Trial: 29666297
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of everolimus by mouth (PO) weekly
Trial: 29666297
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of everolimus PO daily
Trial: 29667940
Drug: Saphenous nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saphenous nerve block with 10 mL 0.5% bupivacaine with 1:200,000 epinephrine
Trial: 29667940
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group receiving 10 mL saline
Trial: 29668600
Drug: Promoter methylation
RxNorm normalized name: methylal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promoter methylation analysis for selected genes and tissue microarray for clinically relevant proteins (e.g., PD-L1, Erb-2, VEGFR2).
Trial: 29669391
Drug: Fostamatinib (a
RxNorm normalized name: fostamatinib (as disodium hexahydrate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fostamatinib (a small molecule inhibitor of Syk)
Trial: 29669701
Drug: Crizotinib 250
RxNorm normalized name: crizotinib 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crizotinib 250 mg twice per day (oral) on a continuous daily dosing schedule for 21 days until disease progression, unacceptable toxicity, or patient refusal.
Trial: 29669753
Drug: Ibrutinib 560
RxNorm normalized name: ibrutinib 560 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib 560 mg orally daily
Trial: 29669753
Drug: Ibrutinib 840
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ibrutinib 840 mg orally daily
Trial: 29669753
Drug: Ibrutinib (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib (both doses)
Trial: 29669936
Drug: HPV-16 E7-specific
RxNorm normalized name: HPV 16 E7/HSP65 vaccine
DrugBank: Verpasep caltespen (DB04959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV-16 E7-specific TCR T cell therapy
Trial: 29670761
Drug: CZP 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CZP 400 mg Q4W
Trial: 29672891
Drug: Glecaprevir/pibrentasvir (300/120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glecaprevir/pibrentasvir (300/120 mg) once daily for 12 weeks
Trial: 29673370
Drug: Early initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Early initiation of renal replacement therapy (RRT) within 6 hours
Trial: 29673370
Drug: Standard initiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard initiation of renal replacement therapy (RRT) by urgent indication
Trial: 29673379
Drug: Erythropoietin (EPO)
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (EPO) 40,000 IU/ml
Trial: 29673381
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (weekly monitoring survey)
Trial: 29673890
Drug: FDC drug
RxNorm normalized name: DYE FDC BLUE #1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC drug (80 mg of telmisartan and 20 mg of rosuvastatin)
Trial: 29673942
Drug: Tick-borne encephalitis
RxNorm normalized name: Tick-borne encephalitis vaccine
DrugBank: Tick-borne encephalitis vaccine (whole virus, inactivated) (DB16611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tick-borne encephalitis (TBE) booster vaccine
Trial: 29675856
Drug: PKC inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PKC inhibitor GF 109203X
Trial: 29675856
Drug: Rho kinase
RxNorm normalized name: Rho(D) immune globulin Injection [WinRho]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rho kinase inhibitor Y-27632
Trial: 29675856
Drug: Combined intervention
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined intervention of PKC inhibitor and Rho kinase inhibitor
Trial: 29677353
Drug: Subretinal delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subretinal delivery (high dose: 1 × 10^12 vg)
Trial: 29677353
Drug: Subretinal delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subretinal delivery (low dose: 1 × 10^11 vg)
Trial: 29678146
Drug: Chemotherapy including
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Chemotherapy including S-1 (IS)
Trial: 29678146
Drug: Chemotherapy not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy not including S-1 (NIS)
Trial: 29678476
Drug: Cabazitaxel plus
RxNorm normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabazitaxel plus Lapatinib (intravenous cabazitaxel 20 mg/m²)
Trial: 29678804
Drug: iWaWa treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iWaWa treatment (8 weeks)
Trial: 29680880
Drug: PRO-122 (preservative-free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRO-122 (preservative-free fixed combination)
Trial: 29680880
Drug: KOF (0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KOF (0.5% timolol + 0.2% brimonidine + 2.0% dorzolamide fixed combination)
Trial: 29681490
Drug: Dimethyl fumarate
RxNorm normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dimethyl fumarate (120 mg twice daily on days one to seven; 240 mg twice a day thereafter)
Trial: 29681973
Drug: Massage Therapy
RxNorm normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage Therapy
Trial: 29681973
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Massage Therapy and Abdominal Hypopressive Gymnastics
Trial: 29682131
Drug: Noninvasive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noninvasive therapy using a biostimulation laser over 12 sessions performed every second day
Trial: 29682332
Drug: ALK inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALK inhibitors
Trial: 29682332
Drug: Anti-PD1 inhibitors
RxNorm normalized name: anti-inhibitor coagulant complex
DrugBank: Anti-inhibitor coagulant complex (DB13151)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-PD1 inhibitors
Trial: 29682773
Drug: Hydrocortisone (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (higher daily doses)
Trial: 29683544
Drug: High-dosed folate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dosed folate supplements (5 mg folic acid per day)
Trial: 29683544
Drug: Iron supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplements (200 mg ferrous sulphate per day)
Trial: 29683562
Drug: Oral osimertinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral osimertinib 80 mg
Trial: 29683562
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) osimertinib 100 μg microtracer dose
Trial: 29684022
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of ceftriaxone and azithromycin
Trial: 29684022
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with ceftriaxone
Trial: 29684022
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of azithromycin and cefexime
Trial: 29684022
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with azithromycin
Trial: 29685594
Drug: Vaxem™ Hib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaxem™ Hib (intramuscular injection)
Trial: 29686173
Drug: Insulin treatment
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin treatment for diabetes
Trial: 29687077
Drug: Single-injection intrathecal
RxNorm normalized name: ziconotide
DrugBank: Ziconotide (DB06283)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-injection intrathecal analgesia (IA)
Trial: 29689135
Drug: Intravenous alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous alteplase (0.9mg/kg)
Trial: 29689485
Drug: High-dose dronabinol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dronabinol (180-240 mg/day; 60-80 mg tid)
Trial: 29689485
Drug: Low-dose dronabinol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dronabinol (120 mg/day; 40 mg tid)
Trial: 29690880
Drug: Lower forced
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower forced expiratory volume in one second after bronchodilator
Trial: 29691182
Drug: Adjunctive protective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive protective drapes
Trial: 29691182
Drug: No adjunctive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No adjunctive protective drapes (implied control)
Trial: 29691270
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of high-sensitivity cardiac troponin I (hs-cTnI) and high-sensitivity cardiac troponin T (hs-cTnT) concentrations.
Trial: 29691270
Drug: hs-cTnI and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs-cTnI and hs-cTnT concentrations with optimized cut-off values (sum: 9 ng/L, product: 18 ng/L).
Trial: 29692980
Drug: NCI-sponsored uterine
RxNorm normalized name: gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NCI-sponsored uterine cervix cancer radiation-chemotherapy intervention clinical trial (NCT02466971)
Trial: 29693476
Drug: Amoxicillin (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (1500 mg/d for 7 days)
Trial: 29693476
Drug: Vancomycin (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin (1500 mg/d for 7 days)
Trial: 29693476
Drug: Placebo (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1500 mg/d for 7 days)
Trial: 29695165
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran etexilate 75 mg BID for ≥7 days
Trial: 29695384
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy (thrombectomy, balloon angioplasty, stenting, local fibrinolysis, piercing)
Trial: 29695384
Drug: No endovascular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No endovascular therapy
Trial: 29695516
Drug: INCB040093 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCB040093 100 mg twice daily (monotherapy)
Trial: 29695516
Drug: INCB040093 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCB040093 100 mg twice daily + itacitinib 300 mg once daily (combination)
Trial: 29696202
Drug: Topical antiviral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical antiviral drug AV2
Trial: 29696238
Drug: Gender- and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gender- and culturally-sensitive weight loss intervention (GCSWLI) for 24 weeks, including a 12-week in-person phase with weekly sessions and a 12-week follow-up with bi-weekly phone calls.
Trial: 29699493
Drug: Non-adherent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-adherent treatment (62.1% of patients)
Trial: 29699493
Drug: Over-treatment in
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Over-treatment in general-ward patients (52.3% over-treated)
Trial: 29699493
Drug: Under-treatment in
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Under-treatment in ICU patients (71.4% under-treated)
Trial: 29699493
Drug: Under-treatment in
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Under-treatment in general-ward patients with risk factors for PA infection (22.9% under-treated)
Trial: 29699493
Drug: Under-treatment in
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Under-treatment in ICU patients with risk factors for PA infection (74.2% under-treated)
Trial: 29700101
Drug: Decision aid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decision aid (DA) in combination with a brief Q&A session with a genetic counsellor
Trial: 29700172
Drug: Post-transplant infusion
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-transplant infusion of cyclophosphamide
Trial: 29700872
Drug: Omalizumab-supplemented Oral
RxNorm normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Omalizumab-supplemented Oral Immunotherapy (OIT)
Trial: 29701107
Drug: Adjunctive naturopathic
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive naturopathic oncology (NO) specialty care
Trial: 29703712
Drug: Topically applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topically applied growth factors combined with protease inhibitor wound dressings
Trial: 29703851
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups continue weekly self-administered subcutaneous MTX treatment (15-25 mg/week)
Trial: 29705265
Drug: GS-0976 20
RxNorm normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GS-0976 20 mg orally once daily for 12 weeks
Trial: 29705733
Drug: Topical immunosuppression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical immunosuppression for GVHD
Trial: 29706508
Drug: Air kerma
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air kerma radiation dose
Trial: 29707537
Drug: Inertial Measurement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inertial Measurement Unit sensors during daily life
Trial: 29707537
Drug: Daily-life recorded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily-life recorded kinematics
Trial: 29707537
Drug: Daily-life activities
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily-life activities
Trial: 29709062
Drug: Chemo-immunotherapy followed
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemo-immunotherapy followed by radio-immunotherapy and 2 years of rituximab maintenance
Trial: 29709062
Drug: Radio-immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radio-immunotherapy
Trial: 29709062
Drug: Post radio-immunotherapy
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post radio-immunotherapy
Trial: 29709062
Drug: Post treatment
RxNorm normalized name: HYDROCORTISONE 1 mg in 1 g TOPICAL CREAM [Post Treatment Balm]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post treatment
Trial: 29709335
Drug: Adherence to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adherence to insulin therapy
Trial: 29710075
Drug: Gabapentin 300
RxNorm normalized name: gabapentin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 300 mg twice daily
Trial: 29712654
Drug: Single-Dose Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-Dose Oral LCB01-0371, a novel oxazolidinone
Trial: 29713493
Drug: EcN suspension
RxNorm normalized name: Ecnoglutide
DrugBank: Ecnoglutide (DB19019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EcN suspension orally for 3 weeks
Trial: 29713493
Drug: EcN treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EcN treatment
Trial: 29713524
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of Ranibizumab (IVR)
Trial: 29713524
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of Bevacizumab (IVB)
Trial: 29715056
Drug: Venetoclax 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax 400 mg per day after an initial dose ramp up
Trial: 29715056
Drug: Venetoclax for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax for patients who received prior kinase inhibitors
Trial: 29716640
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (10 mg/kg loading dose followed by 5 mg/kg/h maintenance infusion)
Trial: 31201186
Drug: Auditory Brainstem
RxNorm normalized name: Sus scrofa brainstem preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auditory Brainstem Implant (ABI)